A Phase 2/3 interventional study of Avacincaptad Pegol and Sham in Geographic Atrophy and Dry Age-Related Macular Degeneration, sponsored by IVERIC bio, Inc.. Completed at 78 sites in 7 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-06-10.
Sponsored by IVERIC bio, Inc. (part of Astellas Pharma Inc) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.
Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 27th largest by enrollment of the 107 interventional ones that give a count, is one of 6 that started in 2015, is one of 5 in phase 2/3, and was the 45th registered.
188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.
Browse Geographic Atrophy studies →35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States
Ages 50+
Biojiva LLC · Sites in United States, Australia
Ages 55+
Sitala Bio LTD · Sites in United States, Argentina, Australia and 4 more countries
Ages 60+
University of Utah · Sites in United States
Ages 65–90
Cellio Therapeutics Inc · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 65 · Phase 3 20
First in 2000; this study’s year is marked. 6 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 286 is above the median of 70 across 141 interventional studies indexed under Geographic Atrophy.
Median enrollment 98 across the 107 interventional studies, 138 across the 24 observational. Of the 79 that completed or were terminated, 40 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
109 of 131 have an industry lead sponsor. The 10 most frequent:
This study is registered under IVERIC bio, Inc., one of the names counted as Astellas Pharma Inc. Under that name alone:
IVERIC bio, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Astellas Pharma Inc has 8 studies filed under Geographic Atrophy — fewer than ten, so there is no comparison to draw.
12 of the studies in Geographic Atrophy with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05949593Phase 3Belite Bio, IncPhase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy | 2027-06-30 |
| NCT06510816Phase 3Annexon, Inc.A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | 2027-07-31 |
| NCT06769048Boehringer IngelheimA Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy | 2026-12-22 |
| NCT07747662University of Wisconsin, MadisonAdaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) Sub-study | 2027-02 |
| NCT07144137Complement TherapeuticsA Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA) | 2027-03-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 131 studies in Geographic Atrophy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objectives of this study were to evaluate the safety and efficacy of Zimura intravitreal (IVT) administration when administered in participants with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).
Participants will receive monthly intravitreal injections of Zimura or Sham for 18 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants received 1 mg of Avacincaptad Pegol in the study eye administered via IVT injection (50 µL) on Day 1 and monthly up to 18 months.
Drug: Avacincaptad Pegol
Participants received 2 mg of Avacincaptad Pegol in the study eye administered via IVT injection (100 µL) on Day 1 and monthly up to 18 months.
Drug: Avacincaptad Pegol
Participants received a Sham injection of an empty, needleless syringe administered in the study eye on Day 1 and monthly up to 18 months.
Other: Sham
Participants received 2 mg of Avacincaptad Pegol in the study eye administered via IVT injection (100 µL) and a subsequent Sham administration on Day 1 and monthly up to 18 months.
Drug: Avacincaptad Pegol · Other: Sham
Participants received 4 mg of Avacincaptad Pegol in the study eye administered via two consecutive IVT injections (2 x 100 µL) on Day 1 and monthly up to 18 months.
Drug: Avacincaptad Pegol
Participants received two consecutive Sham injections of empty, needleless syringes administered in the study eye on Day 1 and monthly up to 18 months.
Other: Sham
Avacincaptad Pegol 20 mg/mL solution for intravitreal (IVT) injection
Also known as: Zimura (previous name), IZERVAY, ARC1905
The Sham procedure included the blunt opening of an empty, needleless syringe barrel placed on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection.
Change From Baseline in Geographic Atrophy as Measured by Fundus Autofluorescence
The least squares mean change in geographic atrophy (GA) from baseline to Month 12 was measured by fundus autofluorescence (FAF). The square root of the GA area was used in the analysis. Per statistical analysis plan, only the Zimura 2 mg and 4 mg groups were evaluated for this primary endpoint; the Zimura 1 mg group was for descriptive purposes only.
Time frame: Baseline and 12 months
Change From Baseline in Best Corrected Visual Acuity Using Early Treatment Diabetic Retinopathy Study Letters
The least squares mean change in best-corrected visual acuity (BCVA) from baseline to Month 12 was measured using early treatment diabetic retinopathy study \[ETDRS\] letters. Per statistical analysis plan, only the Zimura 2 mg and 4 mg groups were evaluated for the secondary endpoints; the Zimura 1 mg group was for descriptive purposes only.
Time frame: Baseline and 12 months
Change From Baseline in Low Luminance BCVA Using Early Treatment Diabetic Retinopathy Study Letters
The least squares mean change in low luminance (LL) BCVA from baseline to Month 12 was measured using ETDRS letters. Per statistical analysis plan, only the Zimura 2 mg and 4 mg groups were evaluated for the secondary endpoints; the Zimura 1 mg group was for descriptive purposes only.
Time frame: Baseline and 12 months
| Milestone | Zimura 1 mg [Part 1] | Zimura 2 mg [Part 1] | Sham [Part 1] | Zimura 2 mg (Zimura 2mg+Sham) [Part 2] | Zimura 4 mg (Zimura 2mg+Zimura 2mg) [Part 2] | Sham (Sham+Sham) [Part 2] |
|---|---|---|---|---|---|---|
| Started | 26 | 25 | 26 | 42 | 83 | 84 |
| Month 12 | 23 | 19 | 19 | 34 | 56 | 72 |
| Completed | 22 | 18 | 17 | 30 | 46 | 68 |
| Not completed | 4 | 7 | 9 | 12 | 37 | 16 |
| Withdrew: Adverse event | 0 | 0 | 1 | 1 | 2 | 1 |
| Withdrew: Investigator decision | 0 | 0 | 0 | 1 | 2 | 1 |
| Withdrew: Sponsor decision | 1 | 2 | 1 | 5 | 13 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 | 0 | 0 | 1 |
| Withdrew: Death | 1 | 0 | 0 | 1 | 1 | 1 |
| Withdrew: Withdrawal by subject | 2 | 5 | 4 | 4 | 17 | 8 |
| Withdrew: Placed in hospice care | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Participant non-compliance | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Concern over coronavirus disease care | 0 | 0 | 0 | 0 | 2 | 1 |
The least squares mean change in geographic atrophy (GA) from baseline to Month 12 was measured by fundus autofluorescence (FAF). The square root of the GA area was used in the analysis. Per statistical analysis plan, only the Zimura 2 mg and 4 mg groups were evaluated for this primary endpoint; the Zimura 1 mg group was for descriptive purposes only.
| millimeters (mm) | Zimura 2 mg [Part 1 & Part 2 Combined] | Sham [Part 1 & Part 2 Combined] | Zimura 4 mg [Part 2] | Sham [Part 2] |
|---|---|---|---|---|
| Change From Baseline in Geographic Atrophy as Measured by Fundus Autofluorescence | 0.292 ± 0.077 | 0.402 ± 0.075 | 0.321 ± 0.074 | 0.444 ± 0.072 |
The least squares mean change in best-corrected visual acuity (BCVA) from baseline to Month 12 was measured using early treatment diabetic retinopathy study \[ETDRS\] letters. Per statistical analysis plan, only the Zimura 2 mg and 4 mg groups were evaluated for the secondary endpoints; the Zimura 1 mg group was for descriptive purposes only.
| ETDRS Letters | Zimura 2 mg [Part 1 & Part 2 Combined] | Sham [Part 1 & Part 2 Combined] | Zimura 4 mg [Part 2] | Sham [Part 2] |
|---|---|---|---|---|
| Change From Baseline in Best Corrected Visual Acuity Using Early Treatment Diabetic Retinopathy Study Letters | -7.90 ± 2.66 | -9.29 ± 2.59 | -3.79 ± 3.11 | -3.51 ± 2.99 |
The least squares mean change in low luminance (LL) BCVA from baseline to Month 12 was measured using ETDRS letters. Per statistical analysis plan, only the Zimura 2 mg and 4 mg groups were evaluated for the secondary endpoints; the Zimura 1 mg group was for descriptive purposes only.
| ETDRS Letters | Zimura 2 mg [Part 1 & Part 2 Combined] | Sham [Part 1 & Part 2 Combined] | Zimura 4 mg [Part 2] | Sham [Part 2] |
|---|---|---|---|---|
| Change From Baseline in Low Luminance BCVA Using Early Treatment Diabetic Retinopathy Study Letters | -1.03 ± 3.40 | -1.41 ± 3.30 | 1.53 ± 3.53 | 2.97 ± 3.39 |
Collected over Adverse events were recorded starting at Day 1 after the first dose of study drug and continuing until 30 days after the last dose or until the last follow-up visit required by the protocol, whichever comes later (up to approximately 18 months from first dose).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zimura 1 mg [Part 1] | 1/26 (3.8%) | 3/26 (11.5%) | 13/26 (50%) |
| Zimura 2 mg [Part 1] | 0/25 (0%) | 4/25 (16%) | 13/25 (52%) |
| Sham [Part 1] | 0/26 (0%) | 7/26 (26.9%) | 10/26 (38.5%) |
| Zimura 2 mg (Zimura 2mg+Sham) [Part 2] | 1/42 (2.4%) | 8/42 (19%) | 34/42 (81%) |
| Zimura 4 mg (Zimura 2mg+Zimura 2mg) [Part 2] | 1/83 (1.2%) | 21/83 (25.3%) | 66/83 (79.5%) |
| Sham (Sham+Sham) [Part 2] | 1/84 (1.2%) | 21/84 (25%) | 49/84 (58.3%) |
| Zimura (Any Dose) [Part 1 & Part 2 Combined] | 3/176 (1.7%) | 36/176 (20.5%) | 126/176 (71.6%) |
| Sham [Part 1 & Part 2 Combined] | 1/110 (0.9%) | 28/110 (25.5%) | 59/110 (53.6%) |
| Event | Zimura 1 mg [Part 1] | Zimura 2 mg [Part 1] | Sham [Part 1] | Zimura 2 mg (Zimura 2mg+Sham) [Part 2] | Zimura 4 mg (Zimura 2mg+Zimura 2mg) [Part 2] | Sham (Sham+Sham) [Part 2] | Zimura (Any Dose) [Part 1 & Part 2 Combined] | Sham [Part 1 & Part 2 Combined] |
|---|---|---|---|---|---|---|---|---|
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/26 | 1/25 | 0/26 | 0/42 | 0/83 | 0/84 | 1/176 | 0/110 |
| CholelithiasisHepatobiliary disorders | 0/26 | 1/25 | 0/26 | 0/42 | 0/83 | 0/84 | 1/176 | 0/110 |
| CellulitisInfections and infestations | 0/26 | 1/25 | 0/26 | 1/42 | 0/83 | 0/84 | 2/176 | 0/110 |
| Femur fractureInjury, poisoning and procedural complications | 0/26 | 1/25 | 1/26 | 0/42 | 1/83 | 0/84 | 2/176 | 1/110 |
| Ulna fractureInjury, poisoning and procedural complications | 0/26 | 1/25 | 0/26 | 0/42 | 0/83 | 0/84 | 1/176 | 0/110 |
| Cerebrovascular accidentNervous system disorders | 1/26 | 1/25 | 0/26 | 0/42 | 1/83 | 1/84 | 3/176 | 1/110 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/26 | 1/25 | 0/26 | 0/42 | 1/83 | 3/84 | 2/176 | 3/110 |
| Ventricular extrasystolesCardiac disorders | 1/26 | 0/25 | 0/26 | 0/42 | 0/83 | 0/84 | 1/176 | 0/110 |
| Coronary artery diseaseCardiac disorders | 0/26 | 0/25 | 1/26 | 0/42 | 0/83 | 2/84 | 0/176 | 3/110 |
| Lower gastrointestinal haemorrhageGastrointestinal disorders | 1/26 | 0/25 | 0/26 | 0/42 | 0/83 | 0/84 | 1/176 | 0/110 |
| Event | Zimura 1 mg [Part 1] | Zimura 2 mg [Part 1] | Sham [Part 1] | Zimura 2 mg (Zimura 2mg+Sham) [Part 2] | Zimura 4 mg (Zimura 2mg+Zimura 2mg) [Part 2] | Sham (Sham+Sham) [Part 2] | Zimura (Any Dose) [Part 1 & Part 2 Combined] | Sham [Part 1 & Part 2 Combined] |
|---|---|---|---|---|---|---|---|---|
| Conjunctival haemorrhage *Eye disorders | 2/26 | 2/25 | 1/26 | 9/42 | 28/83 | 12/84 | 41/176 | 13/110 |
| Intraocular pressure increasedInvestigations | 1/26 | 2/25 | 0/26 | 4/42 | 19/83 | 1/84 | 26/176 | 1/110 |
| FallInjury, poisoning and procedural complications | 0/26 | 0/25 | 0/26 | 8/42 | 6/83 | 7/84 | 14/176 | 7/110 |
| Neovascular age-related macular degeneration*Eye disorders | 3/26 | 2/25 | 2/26 | 7/42 | 11/83 | 2/84 | 23/176 | 4/110 |
| Urinary tract infectionInfections and infestations | 2/26 | 0/25 | 2/26 | 7/42 | 10/83 | 8/84 | 19/176 | 10/110 |
| NasopharyngitisInfections and infestations | 1/26 | 3/25 | 0/26 | 4/42 | 3/83 | 5/84 | 11/176 | 5/110 |
| Vitreous detachment*Eye disorders | 3/26 | 0/25 | 0/26 | 2/42 | 4/83 | 6/84 | 9/176 | 6/110 |
| Conjunctival hyperaemia*Eye disorders | 0/26 | 0/25 | 0/26 | 3/42 | 9/83 | 4/84 | 12/176 | 4/110 |
| Eye pain*Eye disorders | 0/26 | 1/25 | 0/26 | 1/42 | 8/83 | 3/84 | 10/176 | 3/110 |
| Punctate keratitis*Eye disorders | 0/26 | 0/25 | 0/26 | 4/42 | 6/83 | 8/84 | 10/176 | 8/110 |
| Age, Categorical(Participants) | Zimura 1 mg [Part 1] | Zimura 2 mg [Part 1] | Sham [Part 1] | Zimura 2 mg (Zimura 2mg+Sham) [Part 2] | Zimura 4 mg (Zimura 2mg+Zimura 2mg) [Part 2] | Sham (Sham+Sham) [Part 2] | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 4 | 2 | 6 | 5 | 4 | 24 |
| >=65 years | 23 | 21 | 24 | 36 | 78 | 80 | 262 |
| Sex: Female, Male(Participants) | Zimura 1 mg [Part 1] | Zimura 2 mg [Part 1] | Sham [Part 1] | Zimura 2 mg (Zimura 2mg+Sham) [Part 2] | Zimura 4 mg (Zimura 2mg+Zimura 2mg) [Part 2] | Sham (Sham+Sham) [Part 2] | Total |
|---|---|---|---|---|---|---|---|
| Female | 15 | 18 | 18 | 27 | 58 | 61 | 197 |
| Male | 11 | 7 | 8 | 15 | 25 | 23 | 89 |
| Ethnicity (NIH/OMB)(Participants) | Zimura 1 mg [Part 1] | Zimura 2 mg [Part 1] | Sham [Part 1] | Zimura 2 mg (Zimura 2mg+Sham) [Part 2] | Zimura 4 mg (Zimura 2mg+Zimura 2mg) [Part 2] | Sham (Sham+Sham) [Part 2] | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 1 | 0 | 1 | 1 | 5 |
| Not Hispanic or Latino | 25 | 24 | 25 | 42 | 82 | 83 | 281 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Zimura 1 mg [Part 1] | Zimura 2 mg [Part 1] | Sham [Part 1] | Zimura 2 mg (Zimura 2mg+Sham) [Part 2] | Zimura 4 mg (Zimura 2mg+Zimura 2mg) [Part 2] | Sham (Sham+Sham) [Part 2] | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| White | 25 | 25 | 25 | 42 | 82 | 82 | 281 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Ran from Dec 2015 to primary completion in Sep 2019, 45 months.
Results were first posted in May 2023, 3 years 7 months after primary completion. A results delay was requested in Sep 2020.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Avacincaptad pegol